A Phase II Trial of Trastuzumab Combined With Irinotecan in Patients With Advanced HER2-positive Chemotherapy-refractory Gastric Cancer (OGSG1203 HERBIS-5): Final Results
These findings indicate that irinotecan plus trastuzumab is feasible with modest potential efficacy against chemotherapy-refractory advanced HER2-positive gastric cancer.
Authors
- Hisato Kawakami (ORCID: https://orcid.org/0000-0002-3280-4850)
- Yutaka Kimura (ORCID: https://orcid.org/0000-0002-1823-9234)
- Daisuke Sakai (ORCID: https://orcid.org/0000-0003-4189-9270)
- Yutaka Isozaki
- Yukinori Kurokawa (ORCID: https://orcid.org/0000-0002-2883-0132)
- Shunji Endo (ORCID: https://orcid.org/0000-0003-0720-4156)
- Ryohei Kawabata (ORCID: https://orcid.org/0000-0001-7386-1096)
- Taroh Satoh (ORCID: https://orcid.org/0000-0002-4615-2638)
- Kazumasa Fujitani (ORCID: https://orcid.org/0000-0003-4954-5047)
- Toshio Shimokawa (ORCID: https://orcid.org/0000-0002-2256-0282)
- Naotoshi Sugimoto (ORCID: https://orcid.org/0000-0003-1995-5002)
- Kazuhiro Nishikawa (ORCID: https://orcid.org/0000-0003-1213-2732)
- Jin Matsuyama (ORCID: https://orcid.org/0000-0001-9060-282X)
- Motohiro Hirao (ORCID: https://orcid.org/0000-0002-6509-6416)
- Junji Kawada
- Tomono Kawase
- Yoshio Oka
Institutions
- Wakayama Medical University (JP)
- Osaka Prefectural Medical Center (JP)
- Osaka National Hospital (JP)
- Nishinomiya Municipal Central Hospital (JP)
- Osaka City General Hospital (JP)
- Sakai Municipal Hospital (JP)
- Naga Municipal Hospital (JP)
- Matsushita Memorial Hospital (JP)
- Osaka International Cancer Institute (JP)
- Nippon Medical School Hospital (JP)
- Osaka University Hospital (JP)
- Kindai University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.21873/anticanres.17495
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00